Insulet Corp (PODD) Shares Surge 3.5% -- What GF Score of 82 Tells Investors
On May 18, 2026, Insulet Corp (PODD) shares rose 3.5% to a current price of $152.49. Over the past 52 weeks, the stock has fluctuated between a high of $354.88
PODD - Insulet Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$232.18
DETAILS
HIGH:
$280.00
LOW:
$198.00
MEDIAN:
$237.00
CONSENSUS:
$232.18
UPSIDE:
49.92%
Stock News
Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insulet: An Opportune Time To Get Involved
Insulet delivered robust Q1 2026 results, with revenue up 34% to $762M and operating margins expanding to 17.5%. Insulet raised full-year guidance to 21-23% sales growth and expects adjusted earnings to exceed $6.25 per share, reflecting strong Omnipod 5 adoption. Valuation has rebounded, with shares trading at 70x forward earnings and 10x sales, leaving little room for error amid decelerating growth.
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More
Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set of new highs for the S&P 500 and the Nasdaq, as AI fever overshadowed Iran's peace counteroffer dismissal on Monday. The stock market opened lower on the rejection of President Trump's peace offering, but buyers once again circled the... Here Are Tuesday's Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe's, Matador Resources, Toast and More
Why Insulet (PODD) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript
Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript
Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Insulet (PODD) Q1 Earnings and Revenues Top Estimates
Insulet (PODD) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.02 per share a year ago.
Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand
Insulet raised its annual revenue growth forecast on Wednesday after reporting better-than-expected quarterly results, driven by strong demand for its tubeless insulin pumps that eliminate the need for daily injections.
Insulet Reports First Quarter 2026 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company's guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4.
Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the publication of its 2025 Sustainability Report, showcasing progress across its operations, products, people, and community. The report underscores how Insulet's sustainability strategy continues to strengthen its mission of transforming life for people with diabetes while preserving the health of.
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
Insulet (PODD) Upgraded to Buy: Here's Why
Insulet (PODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes.
Insulet Corp (PODD) Shares Surge 7.6% -- What GF Score of 85 Tells Investors
On April 30, 2026, Insulet Corp (PODD) shares rose 7.6% today, bringing the current price to $172.14. However, the stock has faced significant volatility, with
PAHC vs. PODD: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Insulet (PODD). But which of these two stocks presents investors with the better value opportunity right now?
FDA Flags High-Risk Recall Of Insulet's Omnipod 5 Pods Over Insulin Delivery Concerns
The U.S. Food and Drug Administration (FDA) has classified a recall of Insulet Corporation's (NASDAQ:PODD) Omnipod 5 Pods as its most serious type, warning that continued use of affected devices could result in severe injury or death.
Insulet to Participate in BofA Securities 2026 Health Care Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 9:20 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet C.
Analyzing Insulet (NASDAQ:PODD) and NWT Uranium (OTCMKTS:CPTRF)
NWT Uranium (OTCMKTS:CPTRF - Get Free Report) and Insulet (NASDAQ: PODD - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends. Analyst Ratings This is a breakdown of recent recommendations
Price Targets
Insulet price target lowered to $237 from $277 at Goldman Sachs
$237.00
(was $160.40)
Goldman Sachs
Insulet price target lowered to $280 from $325 at RBC Capital
$280.00
(was $161.09)
Shagun Singh
·
RBC Capital
Insulet price target lowered to $250 from $315 at Truist
$250.00
(was $157.30)
Richard Newitter
·
Truist Financial
Insulet price target lowered to $200 from $240 at Evercore ISI
$200.00
(was $156.70)
Evercore ISI
Insulet price target lowered to $210 from $300 at Oppenheimer
$210.00
(was $151.28)
Oppenheimer
Insulet price target lowered to $250 from $350 at Stifel
$250.00
(was $151.28)
Stifel Nicolaus
Insulet price target lowered to $249 from $435 at Canaccord
$249.00
(was $151.28)
William Plovanic
·
Canaccord Genuity
Insulet price target lowered to $200 from $330 at Bernstein
$200.00
(was $151.28)
Bernstein
Insulet price target lowered to $198 from $286 at Barclays
$198.00
(was $151.28)
Matt Miksic
·
Barclays
Insulet price target lowered to $260 from $320 at BTIG
$260.00
(was $152.67)
BTIG
Insulet downgraded to Neutral from Buy at Rothschild & Co Redburn
$220.00
(was $192.21)
Redburn Partners
Insulet price target lowered to $315 from $360 at Truist
$315.00
(was $202.28)
Richard Newitter
·
Truist Financial
Insulet price target lowered to $325 from $380 at RBC Capital
$325.00
(was $197.81)
Shagun Singh
·
RBC Capital
Insulet price target lowered to $360 from $390 at Truist
$360.00
(was $246.04)
Truist Financial
Insulet price target lowered to $340 from $370 at Evercore ISI
$340.00
(was $251.21)
Evercore ISI
Insulet price target lowered to $326 from $363 at Goldman Sachs
$326.00
(was $251.38)
David Roman
·
Goldman Sachs
Insulet price target lowered to $300 from $365 at Oppenheimer
$300.00
(was $254.59)
Oppenheimer
Insulet price target lowered to $330 from $380 at Bernstein
$330.00
(was $258.07)
Bernstein
Insulet price target raised to $286 from $274 at Barclays
$286.00
(was $258.07)
Barclays
Insulet Corporation (PODD) PT Lowered to $435 at Canaccord Genuity
$435.00
(was $258.07)
William Plovanic
·
Canaccord Genuity